Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of HBeAg Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a

Conference Reports for NATAP

The Liver Meeting
San Francisco
November 2018


Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of HBeAg Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a

	Reported by Jules Levin AASLD Nov 2019